Every Form 4 that inTEST Corporation (INTT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INTT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTT filings page.
INTEST CORP director Steven J. Abrams reported a non-market gift transfer of common stock. On July 9, 2026, he transferred 3,000 shares of common stock for no consideration to a family trust of which he and his spouse are co-trustees. Following the transactions, he reports 6,000 shares held directly and 102,000 shares held indirectly through the Steven J. Abrams Revocable Trust, and he remains the beneficial owner of the shares held by the trust.
INTEST CORP director Steven J. Abrams reported a gift transfer of 3,000 shares of common stock. On June 29, 2026, he transferred these shares to a family trust for no consideration, characterized as a bona fide gift. After the transaction, he directly holds 9,000 shares and indirectly holds 99,000 shares through the Steven J. Abrams Revocable Trust. The filing states he and his spouse are co-trustees of the family trust and that he remains the beneficial owner of the shares held by that trust, so this is not an open-market sale and does not change his overall economic exposure to INTEST CORP.
INTEST CORP director Karl E. Johnsen reported receiving equity compensation in the form of restricted common shares. On June 17, 2026, he was granted 12,000 restricted shares that will vest in two equal parts on September 30, 2026 and December 31, 2026.
He was also granted 6,000 additional restricted shares that will vest in four equal annual installments beginning on June 17, 2027. These awards were granted at no cash cost to him under the InTest Corporation 2023 Stock Incentive Plan and represent non‑market, compensation-related acquisitions rather than open‑market purchases or sales.
INTEST CORP director Gerald J. Maginnis reported a disposition of 6,000 shares of Common Stock back to the company. This was recorded as a "Disposition to issuer" with a stated price of $0.00 per share. After the transaction, he directly holds 90,057 shares.
INTEST CORP President and CEO Richard B. Rogoff reported a small share disposition tied to taxes rather than an open-market trade. On April 28, 2026, 220 shares of common stock at $16.90 per share were withheld to satisfy tax withholding obligations on vesting restricted stock.
After this tax-withholding disposition, Rogoff directly holds 11,932 shares of common stock. He also has multiple option grants and restricted stock units that give him additional potential exposure to INTEST CORP stock over the next several years as those awards vest or remain exercisable.
INTEST CORP Division President–Electronic Test, Joseph Richard McManus Jr., reported a routine tax-related share disposition. On April 28, 2026, 233 shares of common stock were withheld at $16.90 per share to cover tax obligations on vested restricted stock, leaving him with 35,460 common shares held directly. The filing also lists several employee stock options on common stock with exercise prices between $7.74 and $16.06 expiring from 2031 through 2036, which represent remaining derivative positions rather than new market transactions.
INTEST CORP President and CEO Richard B. Rogoff received a grant of stock options for 300,000 shares of common stock at an exercise price of $13.65 per share. The options expire on March 31, 2036 and were granted under the inTEST Corporation 2023 Stock Incentive Plan in a transaction exempt under Rule 16b-3.
According to the footnotes, this option will vest on the third anniversary of the grant date if the volume weighted average price of the common stock over the final 20 consecutive trading days before that date exceeds specified prices. Rogoff also holds 3,030 restricted stock units that convert one-for-one into common stock and vest in equal installments on March 17, 2027, 2028 and 2029, along with several prior option grants and 12,152 shares of common stock held directly.
inTEST Corp President & CEO Richard N. Grant Jr. reported multiple dispositions of Common Stock on March 31, 2026, all coded as "Disposition to issuer." These were not open-market sales but forfeitures of unvested restricted shares.
Footnotes explain that the forfeited shares were tied to several time-vesting and performance-vesting restricted stock awards granted on March 8, 2023, March 6, 2024, March 17, 2025, and March 16, 2026. After these forfeitures, he continues to hold Common Stock directly and maintains significant option-based exposure.
His remaining derivative holdings include employee stock options to buy Common Stock with exercise prices ranging from $7.74 to $16.06 per share, expiring between 2031 and 2035, such as an option over 112,000 shares at $10.62 per share expiring in 2031.
INTEST CORP director Steven J. Abrams reported a bona fide gift of 9,000 shares of Common Stock. On March 20, 2026, he transferred these shares to a family revocable trust for no consideration. He and his spouse are co-trustees and he remains the beneficial owner of the shares held by the trust.
After the transaction, he directly holds 12,000 shares and indirectly holds 96,000 shares through the Steven J. Abrams Revocable Trust, so his overall economic exposure to INTEST CORP stock is unchanged by this gift transfer.
INTEST CORP divisional president Richard B. Rogoff reported routine equity compensation activity and an RSU vesting. On March 17, 2026, 1,010 restricted stock units converted into the same number of common shares, and 253 common shares were withheld at $14.46 per share to cover tax obligations rather than sold on the market.
On March 16, 2026, he received grants under the 2023 Stock Incentive Plan, including 2,304 common shares, a further 2,304 performance-based restricted shares that may vest in March 2029 at target performance (with up to 3,456 shares possible), and a stock option for 3,895 shares at an exercise price of $14.47 expiring on March 15, 2036.
After these transactions, Rogoff directly held 12,152 common shares. He also retained multiple stock option positions shown in the filing, including options over 13,565 shares at an exercise price of $7.74 expiring on March 17, 2035 and 9,496 shares at $11.33 expiring on March 5, 2034.
INTEST CORP division president Michael F. Goodrich reported equity compensation grants and routine tax withholding. On March 16, 2026, he received 1,843 restricted shares and 1,843 performance-based restricted shares of Common Stock, both granted at $0.00 under the 2023 Stock Incentive Plan.
The performance-based award will vest in March 2029 based on performance criteria, with a maximum of 2,765 shares vesting at top performance. He also received an Employee Stock Option for 3,116 shares at an exercise price of $14.47 per share, expiring on March 15, 2036, vesting in four equal annual installments starting March 16, 2027.
On March 17, 2026, 216 shares of Common Stock were withheld at $14.46 per share to cover tax obligations on vesting restricted stock, leaving 23,155 shares held directly after this tax-withholding disposition. He also holds additional stock options with exercise prices of $7.74 and $11.33 per share, expiring in 2035 and 2034, respectively.
INTEST CORP Division President – Electronic Test, Joseph Richard McManus Jr., reported routine equity compensation changes and related tax withholding. He received 2,535 restricted shares and 2,535 performance-based restricted shares of Common Stock that were granted under the company’s 2023 Stock Incentive Plan and vest over multiple years, including installments starting on March 16, 2027 and potential vesting in March 2029 based on performance.
He also received an employee stock option covering 4,284 shares of Common Stock at an exercise price of $14.47 per share, expiring in 2036, which vests in four equal annual installments beginning on March 16, 2027. To cover tax obligations on the vesting of restricted stock on March 17, 2026, 296 shares of Common Stock were withheld at a price of $14.46 per share. After these transactions, he directly owns 35,693 Common shares and holds several option awards with exercise prices between $7.74 and $16.06 expiring between 2031 and 2035.
inTEST Corp CFO Duncan Gilmour reported equity compensation awards, not open-market trading. He received an employee stock option for 9,736 shares of common stock at an exercise price of $14.47 per share, expiring in 2036, which will vest in four equal annual installments starting March 16, 2027.
He was also granted 5,760 time-based restricted shares that vest in four equal annual installments beginning on March 16, 2027, plus 5,760 performance-based restricted shares that may vest in March 2029 if specified performance goals are met, with a maximum of 8,640 shares eligible to vest at peak performance.
Following these awards, Gilmour holds 67,954 shares of common stock directly and 200 shares indirectly through his spouse, along with multiple previously granted stock options with exercise prices between $7.74 and $16.80 expiring from 2031 through 2035.
inTEST Corp President & CEO Richard N. Grant Jr. reported new equity awards and a small share sale. He received 13,822 restricted shares that vest in four equal annual installments starting on March 16, 2027, and 13,822 performance-based restricted shares that may vest in March 2029 depending on performance, with a maximum of 20,733 shares vesting at above-target results. He was also granted an option for 23,365 shares of common stock at an exercise price of $14.47, vesting over four years beginning on March 16, 2027.
On March 18, 2026, Grant sold 1,636 common shares at a weighted average price of $14.279 per share to satisfy tax withholding obligations tied to restricted stock vesting, under a Rule 10b5-1 trading plan adopted on December 8, 2023. After this sale, he directly owns 212,730 common shares. He also continues to hold multiple option grants with exercise prices ranging from $7.74 to $16.06 and expiration dates between 2031 and 2035.
Maginnis Gerald J. reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Gerald J. Maginnis received an award of 12,000 shares of Common Stock on March 16, 2026. The grant carried a price of $0.0000 per share, indicating a share-based award rather than a market purchase. After this transaction, he directly holds 96,057 shares.
DEWS JOSEPH W IV reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Joseph W. Dews IV received an equity award of 12,000 shares of Common Stock on March 16, 2026. The shares were granted at no cash cost per share as compensation, not bought on the open market. After this award, he directly holds 130,250 shares in total.
ABRAMS STEVEN J reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Steven J. Abrams received a grant of 12,000 shares of Common Stock on March 16, 2026, at no stated purchase price. After this award, he holds 21,000 shares directly. An additional 87,000 shares are held indirectly through the Steven J. Abrams Revocable Trust.
INTEST CORP director Jeffrey A. Beck received an award of 12,000 shares of common stock. The grant was recorded at no cash cost per share and represents a compensation-related acquisition rather than an open-market purchase. After this grant, Beck directly holds 79,500 shares of INTT common stock.
INTEST CORP President & CEO Richard N. Grant Jr. reported open-market sales of company common stock that were used to cover taxes on vesting restricted stock. He sold 1,397 shares at $14.1639 per share and 1,097 shares at $13.3259 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2023. After these transactions, he holds 186,722 common shares directly and maintains multiple employee stock option awards, including options expiring between 2031 and 2035 with exercise prices ranging from $7.7400 to $16.0600.
INTEST CORP Division President–Electronic Test, Joseph Richard McManus Jr., reported tax-related share withholdings rather than open-market trades. On March 6 and 8, 2026, a total of 333 shares of common stock were withheld at $13.24 per share to cover tax obligations on vesting restricted stock. After these transactions, he directly holds 30,919 shares of common stock. He also retains multiple employee stock options, including grants exercisable at $7.74, $8.14, $11.33, $13.13, and $16.06 per share with expirations between 2031 and 2035, several of which vest in equal annual installments.
INTEST CORP division president Richard B. Rogoff reported routine share dispositions to cover taxes on equity compensation. On March 6 and March 8, 2026, a total of 291 shares of common stock were withheld at $13.24 per share to satisfy tax withholding obligations on vesting restricted stock.
After these tax-withholding dispositions, Rogoff directly holds 6,787 shares of common stock. He also holds equity awards that may convert into additional shares, including 4,040 restricted stock units that vest in four equal annual installments starting on March 17, 2026, and several stock option grants covering underlying common shares at exercise prices between $7.74 and $16.06 with expirations from 2032 through 2035.
inTEST Corp division president Michael F. Goodrich reported a routine tax-related share disposition. On March 6, 2026, 148 shares of common stock were withheld at $13.24 per share to cover tax obligations on the vesting of restricted stock, rather than sold in the open market.
Following this withholding, Goodrich directly holds 19,685 shares of inTEST common stock. He also retains employee stock options to buy additional shares, including options with an exercise price of $7.74 per share expiring on March 16, 2035 and options at $11.33 per share expiring on March 5, 2034, which vest in four equal annual installments starting in 2025 and 2026.
INTEST CORP Division President–Electronic Test Joseph Richard McManus Jr. reported a disposition of 2,076 shares of common stock on March 4, 2026, recorded as a “Disposition to issuer” at a price of $0.00 per share. A footnote explains these shares were forfeited under the terms of his performance-based restricted stock award granted on March 8, 2023. After this forfeiture, he directly holds 31,252 common shares. The filing also updates his employee stock option positions, showing several option grants that vest in four equal annual installments beginning on March 17, 2026, March 6, 2025, March 8, 2024, and April 28, 2023, plus one option grant that is fully vested as of the report date.
inTEST Corp CFO Duncan Gilmour reported the disposition of 4,670 shares of common stock to the company on March 4, 2026. The shares were forfeited under a performance-based restricted stock award granted on March 8, 2023. After this, he directly holds 56,434 common shares, several employee stock options that vest in four equal annual installments beginning on March 9, 2023, March 8, 2024, March 6, 2025 and March 17, 2026, and 200 common shares held indirectly by his spouse.
inTEST Corp President & CEO Richard N. Grant Jr. reported the forfeiture of 9,859 shares of Common Stock on March 4, 2026 as a disposition to the issuer. A footnote states these shares were forfeited under the terms of Mr. Grant's performance-based restricted stock award granted on March 8, 2023.
After this forfeiture, Mr. Grant directly held 189,216 shares of Common Stock. The filing also lists several Employee Stock Options (rights to buy), with post-transaction holdings of 2,327, 43,384, 30,536, 16,988, 25,692 and 112,000 options, respectively. Footnotes describe option vesting in four equal annual installments commencing on March 17, 2026, March 6, 2025, March 8, 2024, and March 9, 2023, and note that one option grant is fully vested as of the report date.
inTEST Corporation director reports open-market stock purchase. A company director filed a Form 4 disclosing the purchase of 6,000 shares of inTEST common stock on 11/19/2025 at a price of $7.44 per share in a transaction coded as a purchase. Following this buy, the reporting person directly owns 84,057 shares of inTEST common stock. This filing reflects a change in the director's personal ownership stake rather than an issuance of new shares by the company.